What Suplasyn 1-Shot treats: main uses and benefits

Suplasyn 1-Shot is applied across domains where additional symptomatic support is needed. The core therapeutic domain of this category of medicine is the symptomatic treatment of osteoarthritis (OA). This therapy is relevant in clinical settings that involve acute or unstable symptom patterns, and is considered relevant across therapeutic domains where additional symptomatic support may be part of symptomatic management. The primary use is relevant for conditions associated with acute or disruptive episodes.

---

The product is commonly used to help with managing symptom clusters that create noticeable physiological strain, such as symptoms related to physical discomfort (joint pain and stiffness), that often interfere with daily functioning. The treatment provides support that helps ease the overall symptom burden. The treatment assists with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms. This approach is relevant in contexts involving heightened systemic burden and helps patients cope more steadily with symptom fluctuations.

---

Quick Fact: Relevant for symptoms related to physical discomfort that interfere with daily functioning.

Official Population Eligibility Status

Suplasyn 1-Shot is officially authorized for use in Adults with knee osteoarthritis. Eligibility is defined by clear contraindications and limitations established in regulatory documentation.

Who Must Not Use (Contraindicated)

The medicine is contraindicated and must not be administered to specific patient groups to prevent serious adverse outcomes:

• Patients with documented hypersensitivity or allergy to hyaluronate preparations.
• Individuals presenting with an infection or skin disease in the area designated for the injection site.
• The presence of an active joint infection (septic arthritis) is an absolute non-eligibility criterion.

Age, Pregnancy, and Conditional Use

• Age Restrictions: The safety and effectiveness of the injection have not been established in pediatric patients (under 18 years old), functionally restricting its use to adults.
• Pregnancy and Lactation: Use is not recommended in pregnant or breastfeeding women because official regulatory data regarding safety and effectiveness in these populations are insufficient.
• Conditional Restriction: Treatment may be conditional upon the local joint status, as official labels recommend that substantial joint effusion (excess fluid) be removed or treated prior to administration.

Interactions with other medicines and products

The interaction profile for this intra-articular viscoelastic solution is based on local chemical compatibility and restrictions on co-administration, rather than systemic drug-drug effects.

Contraindicated Combinations and Chemical Incompatibility

Official regulatory documents strictly prohibit contact between the active ingredient, Sodium Hyaluronate, and disinfectants containing quaternary ammonium salts. This is classified as a contraindicated combination due to a direct chemical incompatibility. The active ingredient can precipitate (solidify) when exposed to these substances, such as Benzalkonium Chloride, which affects the physical form and function of the medicine. These substances must therefore not be used for skin preparation at the injection site.

Pharmacodynamic and Administration Restrictions

The regulatory label restricts co-administration with other local injectables. The safety and effectiveness of using this product concomitantly (at the same time or mixed) with other intra-articular injectables, such as local anesthetics or corticosteroids, have not been established in controlled studies.

Systemic Interactions

Due to the localized intra-articular administration and subsequent local metabolism, no systemic pharmacokinetic interactions are documented in regulatory sources. This includes the absence of officially documented interactions with CYP enzymes, drug transporters, food, alcohol, or herbal products.

How Suplasyn 1-Shot Works at a Biological Level

The mechanism of action for Suplasyn 1-Shot is localized and non-systemic, defined by two main mechanistic domains: the modulation of the joint's rheological properties and the regulation of local cellular activity.

Viscosupplementation and Biomechanical Support

This domain covers the immediate physical effect where the injected high-molecular-weight sodium hyaluronate (HA) restores the viscoelastic properties of the depleted synovial fluid. This restoration acts directly as a lubricant and shock absorber, minimizing friction between articular cartilage surfaces and providing biomechanical stabilization against applied load. The restoration of proper biomechanics influences the magnitude of mechanical forces and stress applied across the joint surfaces.

Cellular Modulation and Anti-Catabolic Signaling

This domain involves the long-term biological effect of HA as it binds to receptors (e.g., CD44) on synoviocytes and chondrocytes. This signaling interaction promotes the body's own endogenous production of protective HA and cartilage matrix components while simultaneously suppressing the activity of destructive enzymes like Matrix Metalloproteinases (MMPs) and dampening local inflammatory signals (cytokines). This dual action contributes to the maintenance of the articular tissue structure and its biochemical environment.

Nociceptor Attenuation and Pain Signal Modulation

In addition to biomechanical and anti-inflammatory effects, the injected HA exerts a localized neuromodulatory influence on the sensory nerve endings (nociceptors) in the synovial lining. This desensitization attenuates the transmission of pain signals originating from the joint. The mechanism provides an independent pathway for modulation of nociceptor signaling, influencing the excitability of articular nerves and their response to local stimuli.

Administration Overview

Suplasyn 1-Shot is a sterile solution of sodium hyaluronate designed for a single intra-articular injection. The procedure is performed by a healthcare professional in a clinical setting. The solution is supplied in a graduated, pre-filled syringe to facilitate the delivery of the specific volume required for the treatment.

Preparation for Injection

Before the procedure, the product must reach room temperature. The healthcare professional ensures the injection site is appropriately prepared using standard aseptic techniques. This typically involves cleaning the skin over the joint with an antiseptic solution.

The Procedure

The injection is administered directly into the synovial space of the affected joint. For larger joints, such as the knee, the single-dose format provides the necessary volume of sodium hyaluronate in one application. The professional may use medical imaging, such as ultrasound, to ensure precise placement of the needle within the joint capsule.

If there is excess fluid (joint effusion) present in the joint, it is common practice for the healthcare provider to remove it before injecting the solution. This process, known as aspiration, helps reduce pressure and ensures the sodium hyaluronate is not overly diluted.

Post-Injection Care

After the administration, the injection site is usually covered with a small adhesive bandage. Patients are typically advised to rest the joint and avoid strenuous activities or prolonged weight-bearing exercises for a brief period following the procedure to allow the joint to settle.

Research evidence / Overview of studies for Suplasyn 1-Shot

---

Evidence for Use in Symptomatic Knee Osteoarthritis

Research exploring the application of this type of intra-articular injection has largely focused on symptomatic primary osteoarthritis of the knee. The evidence base includes many controlled studies called Randomized Controlled Trials (RCTs), where researchers compared measured outcomes to a non-active injection, known as a placebo, or to other active treatments. These individual studies have been gathered and analyzed in comprehensive reports known as Systematic Reviews and Meta-analyses.

In these studies, researchers set out to measure changes in two main areas: patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. The studies monitored how symptoms evolved in the observed populations, particularly adults with mild to moderate disease severity. Further understanding of symptom patterns comes from Observational, Non-interventional Studies, which have been used in research exploring how symptoms change over time in real-world settings.

Studies reported measured changes observed during the study period, with some trials describing patterns observed in the measured pain levels compared to the control groups. However, the findings were mixed across various systematic reviews, and evidence quality varies across studies, with some reviews noting challenges in establishing consistent comparative certainty. The duration of most core trials was short-term, typically following patients for only a few months.

---

Evidence for Use in Other Major Joints

Research also explored the application in other large joints, including symptomatic Hip Osteoarthritis and Glenohumeral (Shoulder) Osteoarthritis. For these areas, the evidence pool consists mainly of a smaller number of studies and smaller patient populations compared to the knee.

Studies examined changes in outcomes related to physical discomfort and monitored functional limitations specific to the hip or shoulder joint. Findings describe patterns observed in these studies, where patients reported changes in symptom intensity over defined time intervals. However, data for certain groups remain insufficient. Systematic reviews attempting to synthesize this data have often described the evidence base as limited and heterogeneous due to differences in study designs.

---

Durability of Effect and Long-Term Follow-up

The research base has looked at measured changes during periods of increased symptom activity to understand the time frame over which patterns may be observed. Follow-up durations were limited in the core controlled trials, extending up to six months in many of the real-world observational follow-up studies.

While this research provides insight into short-term changes and outcomes observed during the first six months, there is limited information for long-term outcomes beyond this intermediate period. The measured long-term outcomes are not fully established by controlled trials, and there is an ongoing lack of data describing the durability of measured changes over years.

---

Research in Specific Patient Groups

The studies conducted primarily involved Adults diagnosed with primary osteoarthritis. The research generally focuses on patients with specific disease severity strata, often mild to moderate.

There is limited information available from specific clinical trials for certain subgroups, such as those with highly advanced disease (severe K-L grades) or specific comorbid conditions that were excluded from the primary trials. Sample sizes were modest in some original reports, meaning results apply only to the populations studied.

---

Key Limitations and Uncertainties in the Research Landscape

The evidence highlights what is known—and what is still uncertain. One key limitation is the challenge in separating the measured changes observed in the treatment groups from the non-active effects of the injection procedure (placebo effect), which can also lead to measured changes in pain and function.

The evidence quality varies across studies, and some comparative evidence is lacking. Overall, the certainty remains low for applications outside of the knee. The research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes.

Key Studies & References

1. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis - Clinical Guidelines
2. Efficacy of intra-articular hyaluronic acid injections in hip osteoarthritis: a meta-analysis of randomized controlled trials

Common questions about Suplasyn 1-Shot (FAQ)

Q: How often is Suplasyn 1-Shot typically administered?

Official administration guidelines state that Suplasyn 1-Shot is designed for a single administration as a complete course of treatment for the affected joint. Information regarding the decision to repeat treatment or subsequent courses is typically determined by professional clinical protocols.

Q: How long does it take for Suplasyn 1-Shot to start working?

The mechanism of action is described as having both an immediate physical effect, where it restores the joint fluid’s properties, and a long-term biological effect, which relates to cellular signaling. Researchers measure changes in patient-reported outcomes over time, consistent with this dual action.

Q: How long can the effects of Suplasyn 1-Shot last?

Research documents indicate that follow-up durations in the core controlled trials were limited, with many observational studies tracking measured changes up to six months. Information on outcomes and durability of effect beyond this intermediate period is considered limited and not fully established by controlled trials.

Q: Are there any specific activities I should avoid after getting the injection?

Yes, official administration rules advise patients to rest the injected joint for a period of 24–48 hours immediately following the procedure. Furthermore, official guidance recommends avoiding strenuous activity during the full course of treatment.

Q: Can I drive immediately after receiving Suplasyn 1-Shot?

Official post-injection guidelines advise that the patient should rest the injected joint and avoid strenuous activity immediately following the administration. It is important that these procedural conditions are followed, and activity remains limited until the post-injection rest period has passed.

Q: Are there interactions between Suplasyn 1-Shot and common pain relievers?

Due to the localized intra-articular administration (meaning it stays in the joint), regulatory sources do not document any systemic pharmacokinetic interactions with oral medications. This includes common, orally taken pain relievers.

Q: What should I do if the injection site feels warm or looks red?

Localized discomfort, pain, swelling, and other injection site reactions are classified in official documents as common effects. However, due to the serious risk of joint infection (septic arthritis), official documents indicate that a healthcare provider should be consulted if symptoms like warmth or redness persist, worsen, or are accompanied by a fever.

Q: Does Suplasyn 1-Shot have a known effect on the immune system?

Official documentation notes that rare, but serious, immediate hypersensitivity events (anaphylactoid reactions) have been documented. Separately, the mechanism of action is described as involving the dampening of local inflammatory signals within the joint itself.

Q: What kind of research has been done on this product?

The evidence base summarized in official documents includes a range of research methods used to assess outcomes. These include comparative studies like Randomized Controlled Trials (RCTs), as well as broad reports such as Systematic Reviews, Meta-analyses, and Observational Studies.

Q: Can people who take blood thinners get Suplasyn 1-Shot?

Systemic drug-drug interactions, including those with medications such as blood thinners (anticoagulants), are not documented in official regulatory sources. However, the procedure requires professional administration, during which procedural considerations and potential risks are assessed.

Q: Is Suplasyn 1-Shot the same as other joint injections?

No. Official documents classify Suplasyn 1-Shot as a Viscosupplement and a Rheological modifier, which contain the active ingredient Sodium Hyaluronate. This functional class is distinct from other types of intra-articular injections, such as corticosteroids.

Q: Can Suplasyn 1-Shot be used in joints other than the knee?

Official regulatory authorization for the product is for use in adults with knee osteoarthritis. While research evidence has explored applications and outcomes in other major joints, such as the hip and shoulder, the official authorization is specific to the knee.

Q: What is the difference between Suplasyn 1-Shot and Suplasyn regular?

Suplasyn 1-Shot is distinguished by its designation as a single administration viscosupplement. This means it is designed to deliver the full required dose in one session, unlike other formulations in this product class that utilize multi-injection regimens.

Q: Is Suplasyn 1-Shot considered a first-line treatment option?

Official descriptions of its clinical placement state that this type of product is often utilized in symptomatic relief when non-pharmacologic therapy and simple analgesics have proven insufficient. It is used as part of a therapeutic strategy.

Q: Does Suplasyn 1-Shot help with stiffness?

The goal of viscosupplementation is to restore joint function, which involves lubricating the joint. Studies observe changes in patient mobility and stiffness as part of the measured functional outcomes.

Q: What is the clinical evidence regarding long-term use?

The research base has limited information for outcomes beyond the intermediate period, typically six months. Official documents state that the measured long-term outcomes for use over years are not fully established by controlled trials.

Q: Is Suplasyn 1-Shot available without a prescription?

No, official procedures require that administration must be performed exclusively by a physician using strict aseptic technique. It is not available for purchase without professional administration.

Q: Are there different concentrations of Suplasyn 1-Shot?

The official administration rule defines a standardized single dose, containing 60 mg of Sodium Hyaluronate in 6 ml solution. This specification indicates that Suplasyn 1-Shot is a standardized concentration intended for the single-administration protocol.

Q: Can I have physical therapy after receiving the injection?

Official guidance requires a period of rest and avoidance of strenuous activity immediately following the administration. There are no specific regulatory constraints against appropriate follow-on therapies, provided the initial period of rest and avoidance of strenuous activity is strictly followed.

Q: Is there a limit to how many times a joint can be injected with Suplasyn 1-Shot?

The product is administered as a single complete course of treatment. Decisions about re-treatment for subsequent courses in the same joint are governed by clinical protocols and professional medical assessment over time.

Q: Can people with diabetes use Suplasyn 1-Shot?

Official regulatory documents define specific eligibility constraints, including contraindications such as existing infection or allergy. Diabetes mellitus is not listed as a contraindication or warning in these official product documents.

Q: Does the injection contain preservatives?

The official product identity defines the contents as Sodium Hyaluronate in a sterile aqueous viscoelastic solution. The label advises against using certain disinfectants containing quaternary ammonium salts due to a chemical incompatibility with the active ingredient.

Q: Are there any known interactions with herbal supplements?

Due to the localized intra-articular administration, official regulatory sources note an absence of documented systemic pharmacokinetic interactions with food, alcohol, or herbal products.

Q: Is there any research comparing Suplasyn 1-Shot to no treatment?

Yes, research includes Randomized Controlled Trials (RCTs) where measured outcomes were compared against a non-active injection, known as a placebo. This placebo control is used by researchers to identify changes separate from the non-active effects of the injection procedure itself.

Official Storage and Disposal Requirements

Storage and disposal of Suplasyn 1-Shot are strictly defined by regulatory guidelines to preserve the sterility and integrity of the pre-filled syringe.

Storage Conditions

Requirement	Status
Temperature Range	Store between 2 C and 25 C
Freezing	Do not freeze
Protection	Store in the original carton to protect the syringe
Integrity Check	Do not use if the packaging is damaged or compromised
Child Safety	Keep out of the sight and reach of children

Disposal and Stability

The product is designated for single use only and the syringe must not be reused. Any unused medication and the used syringe must be discarded safely. Disposal should strictly follow local pharmaceutical waste and health authority guidelines to ensure proper handling of medical materials.